search
Back to results

Prevention of Cervical Cancer Through an HPV-based Screen-and-treat Strategy in Malawi

Primary Purpose

Cervical Cancer

Status
Completed
Phase
Not Applicable
Locations
Malawi
Study Type
Interventional
Intervention
Community-based HPV screening strategy
Clinic-based HPV screening strategy
Sponsored by
University of North Carolina, Chapel Hill
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Cervical Cancer

Eligibility Criteria

15 Years - 50 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

Health care providers In-Depth Interviews (IDIs) and Focus Group Discussions:

  • Health care staff member must be currently working at one of the 16 health facilities selected for the study.

Client In-Depth Interviews:

  • Woman must have participated in cervical cancer screening via HPV self-sampling through one of the 16 health facilities during the study period.

Client Exit Surveys:

  • Woman who received or declined VFP and/or CCS services in the catchment area of the targeted facilities.

Endline Household survey:

  • Woman must be between the ages of 15-50 years.

Exclusion Criteria:

Endline Household survey:

  • Woman who has had her cervix removed.

Sites / Locations

  • UNC Project-Malawi

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Model 1 - Clinic Based Screening

Model 2 - Community Based Screening

Arm Description

Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA

Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive

Outcomes

Primary Outcome Measures

Proportion of women who receive cervical cancer screening in Model 2
Effectiveness of community-based cervical cancer screening as measured through Endline Household Surveys
Proportion of women who receive family planning services in Model 2
Effectiveness of integrating community-based cervical cancer screening into family planning services as measured through Endline Household Surveys

Secondary Outcome Measures

Proportion of healthcare workers who report satisfaction with providing cervical cancer services
Acceptability and feasibility of service provision as measured through routine assessments
Proportion of healthcare workers who report satisfaction with providing family planning services
Acceptability and feasibility of service provision as measured through routine assessments
Proportion of clients who report satisfaction with cervical cancer services received at study facilities
Acceptability and feasibility of cervical cancer screening and preventive therapy as measured through client exit surveys
Proportion of clients who report satisfaction with family planning services received at study facilities
Acceptability of family planning services as measured through client exit surveys
Cost of the intervention
The cost per client of adding cervical cancer screening and preventive therapy to voluntary family planning services in each model as measured through routine assessments and client exit surveys

Full Information

First Posted
February 24, 2020
Last Updated
September 22, 2022
Sponsor
University of North Carolina, Chapel Hill
Collaborators
United States Agency for International Development (USAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT04286243
Brief Title
Prevention of Cervical Cancer Through an HPV-based Screen-and-treat Strategy in Malawi
Official Title
UNCPM 21904 - Prevention of Cervical Cancer Through an HPV-based Screen-and-treat Strategy in Malawi: a Cluster Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
March 4, 2020 (Actual)
Primary Completion Date
December 18, 2021 (Actual)
Study Completion Date
December 18, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of North Carolina, Chapel Hill
Collaborators
United States Agency for International Development (USAID)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to determine the acceptability, appropriateness, and feasibility of implementing new strategies to screen and treat eligible women for cervical cancer through a cluster randomized trial of two different models. Both models offer the same screening and treatment algorithm, but one will be based in Voluntary Family Planning (VFP) or other clinics and the second will be based in the community. Participants will be recruited from two districts in Malawi with the highest HIV prevalence in the country: Lilongwe in the Central Region and Zomba in the Southern Region.
Detailed Description
Cervical cancer is largely preventable through screening and preventive therapy. This is a cluster randomized trial that will integrate a novel cervical cancer screen-and-treat algorithm into voluntary family planning (VFP) services via two different models aimed at reducing barriers to screening and treatment in resource limited settings. Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day visual inspection with acetic acid (VIA) for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA. Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive. Participants will be recruited from 16 high HIV-prevalence clinics in either Lilongwe in the Central Region or Zomba in the Southern Region. The broad objective of the project is to compare the effectiveness and budget impact of these two models for averting potential cervical cancer cases and to evaluate the implementation and acceptability of the models in multiple different health care facility settings. A systematic Implementation Evaluation will be conducted throughout implementation of the assigned models at the study health facilities to determine the success/failure in the delivery of intervention packages. The study team will employ the following mixed method data collection assessments: In-Depth Interviews with purposively selected healthcare facility staff and clients in the sampled facilities (N = approximately 60) Focus group discussions (FGDs) with purposively selected in-clinic services providers and HSAs (N = approximately 160) Structured weekly observations of service delivery by clinical mentors using an observation checklist, to observe providers and laboratorians adherence to standards, guidelines and intervention protocols Aggregate collection of routine quantitative service utilization data from adapted family planning and cervical cancer screening registers Implementation of assessment tools to assess changes in service providers' workload Client Exit Surveys with women in the catchment areas of the targeted facilities who received or declined family planning and/or cervical cancer screening services at the facility or in the community (N= approximately 1,000) Time and motion studies to observe visits and staff time spent on counseling, screening and treatment procedures, and managing and testing specimens. Finally, an Endline Household Survey will be completed among a random sample of women selected from all of the facilities' catchment areas (N= approximately 8,000). This survey will ask questions about basic demographic information, reproductive health information, HIV status, distance to the nearest health facility, prior VFP use, VFP use during project implementation, prior cervical cancer screening and preventive therapy (CCSPT) services received, and any CCSPT services received during project implementation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Cancer

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA. Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
8174 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Model 1 - Clinic Based Screening
Arm Type
Active Comparator
Arm Description
Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA
Arm Title
Model 2 - Community Based Screening
Arm Type
Experimental
Arm Description
Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive
Intervention Type
Other
Intervention Name(s)
Community-based HPV screening strategy
Intervention Description
Offering HPV self-collection for cervical cancer screening in the community
Intervention Type
Other
Intervention Name(s)
Clinic-based HPV screening strategy
Intervention Description
Offering HPV self-collection for cervical cancer screening in the clinic
Primary Outcome Measure Information:
Title
Proportion of women who receive cervical cancer screening in Model 2
Description
Effectiveness of community-based cervical cancer screening as measured through Endline Household Surveys
Time Frame
12 months after model implementation
Title
Proportion of women who receive family planning services in Model 2
Description
Effectiveness of integrating community-based cervical cancer screening into family planning services as measured through Endline Household Surveys
Time Frame
12 months after model implementation
Secondary Outcome Measure Information:
Title
Proportion of healthcare workers who report satisfaction with providing cervical cancer services
Description
Acceptability and feasibility of service provision as measured through routine assessments
Time Frame
12 months after model implementation
Title
Proportion of healthcare workers who report satisfaction with providing family planning services
Description
Acceptability and feasibility of service provision as measured through routine assessments
Time Frame
12 months after model implementation
Title
Proportion of clients who report satisfaction with cervical cancer services received at study facilities
Description
Acceptability and feasibility of cervical cancer screening and preventive therapy as measured through client exit surveys
Time Frame
12 months after model implementation
Title
Proportion of clients who report satisfaction with family planning services received at study facilities
Description
Acceptability of family planning services as measured through client exit surveys
Time Frame
12 months after model implementation
Title
Cost of the intervention
Description
The cost per client of adding cervical cancer screening and preventive therapy to voluntary family planning services in each model as measured through routine assessments and client exit surveys
Time Frame
12 months after model implementation

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Woman must be between the ages of 15-50 years
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Health care providers In-Depth Interviews (IDIs) and Focus Group Discussions: Health care staff member must be currently working at one of the 16 health facilities selected for the study. Client In-Depth Interviews: Woman must have participated in cervical cancer screening via HPV self-sampling through one of the 16 health facilities during the study period. Client Exit Surveys: Woman who received or declined VFP and/or CCS services in the catchment area of the targeted facilities. Endline Household survey: Woman must be between the ages of 15-50 years. Exclusion Criteria: Endline Household survey: Woman who has had her cervix removed.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer Tang, MD, MSCR
Organizational Affiliation
University of North Carolina, Chapel Hill
Official's Role
Principal Investigator
Facility Information:
Facility Name
UNC Project-Malawi
City
Lilongwe
Country
Malawi

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Research data that documents, supports, and validates research findings will be made available after the main findings from the final research dataset have been accepted for publication. Access to databases will be available for educational, research, and non-profit purposes. All data to be shared will be stripped of any potentially identifying information. Data will be made available through USAID's Data Development Library (DDL).
IPD Sharing Time Frame
Data will be available within 6 months of publication for an unlimited period
IPD Sharing Access Criteria
Deidentified data will be publicly available through the DDL. Research datasets may also be made available to Malawian and other international investigators who request access. Requests will be evaluated on a case-by-case basis by the study investigators. Investigators proposing to use the data will be asked to provide approval from an ethical review committee and may be asked to execute a data use/sharing agreement with UNC. Data may be shared electronically via password protected files. All data sharing will abide by rules and/or policies defined by USAID, relevant IRBs, U.S. local, state, and federal laws and regulations, as well as Malawian laws and regulations. Data sharing mechanisms will ensure that the rights and privacy of individuals participating in research will be protected at all times.
Citations:
PubMed Identifier
33879259
Citation
Tang JH, Smith JS, McGue S, Gadama L, Mwapasa V, Chipeta E, Chinkhumba J, Schouten E, Ngwira B, Barnabas R, Matoga M, Chagomerana M, Chinula L. Prevention of cervical cancer through two HPV-based screen-and-treat implementation models in Malawi: protocol for a cluster randomized feasibility trial. Pilot Feasibility Stud. 2021 Apr 20;7(1):98. doi: 10.1186/s40814-021-00839-7.
Results Reference
derived

Learn more about this trial

Prevention of Cervical Cancer Through an HPV-based Screen-and-treat Strategy in Malawi

We'll reach out to this number within 24 hrs